Rozanolixizumab
Rozanolixizumab is a humanized monoclonal antibody designed for the treatment of autoimmune diseases. It targets the neonatal Fc receptor (FcRn), which plays a crucial role in the regulation of immunoglobulin G (IgG) antibodies. By inhibiting FcRn, rozanolixizumab reduces the levels of pathogenic IgG antibodies, thereby alleviating symptoms of autoimmune conditions.
Mechanism of Action[edit]
Rozanolixizumab works by binding to the neonatal Fc receptor (FcRn). FcRn is responsible for protecting IgG antibodies from lysosomal degradation, thus prolonging their half-life in the bloodstream. By inhibiting FcRn, rozanolixizumab accelerates the degradation of IgG antibodies, including those that are pathogenic. This reduction in IgG levels can help manage autoimmune diseases where IgG antibodies attack the body's own tissues.
Clinical Applications[edit]
Rozanolixizumab is being investigated for its potential in treating various autoimmune diseases, including:
Development and Approval[edit]
Rozanolixizumab is currently undergoing clinical trials to evaluate its safety and efficacy. The results of these trials will determine its potential approval by regulatory agencies such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Side Effects[edit]
As with any therapeutic antibody, rozanolixizumab may cause side effects. Common side effects observed in clinical trials include:
Related Pages[edit]
- Monoclonal antibody
- Autoimmune disease
- Neonatal Fc receptor
- Myasthenia gravis
- Immune thrombocytopenic purpura
- Chronic inflammatory demyelinating polyneuropathy
References[edit]
External Links[edit]
-
 | This medical article is a stub. You can help WikiMD by expanding the page. |
